NANargess Arandi

Nargess Arandi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nargess Arandi has a total of 87 co-authors. Here are the top co-authors by number of shared publications:

  • Hossein Golmoghaddam

    Department of Pathology School of Medicine, Shiraz University of Medical Sciences Shiraz Iran

    15 shared publications
  • Mani Ramzi

    Hematology Research Center, Shiraz University of Medical Sciences Shiraz Iran

    12 shared publications
  • Mehdi Kalani

    Department of Immunology Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences Shiraz Iran

    9 shared publications
  • Negin Shokrgozar

    Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    7 shared publications
  • Mehdi Dehghani

    Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Stem Cell Transplantation, Shiraz University of Medical Sciences, Shiraz, Iran

    5 shared publications
  • Narges Rezaei

    Shiraz Univ Med Sci, Hematol Res Ctr, Shiraz, Iran

    5 shared publications

Latest Publications

  • High donor regulatory B cells (Bregs) and their rapid recovery are associated with protection from the development of acute graft‐versus‐host disease (aGVHD) following allogeneic hematopoietic stem cell transplantation

    by Mani Ramzi, Maryam Hesamadini, Mohammadnabi Sanaei, Hossein Golmoghaddam, Mehdi Kalani, Nargess Arandi

    Summary: This study aimed to evaluate the peripheral blood donor CD19+CD24hiCD38hi regulatory B‐cell (Breg) content and the Breg recovery rates during 90 days following allogeneic hematopoietic stem cell transplantation (allo‐HSCT) and their correlation with the development of acute graft‐versus‐host disease (aGVHD). Twenty‐four donor–recipient pairs with hematological malignancies who underwent unmanipulated, fully HLA‐matched allo‐HSCT from related siblings were enrolled. The frequency of Bregs and their absolute number were significantly lower in donors whose recipients developed aGVHD (*p = 0.005 and *p = 0.016, respectively). Acute GVHD (+) patients had a significantly diminished percentages of Bregs recovered at days 60 and 90 compared to the aGVHD (−) ones (*p < 0.001 and *p = 0.002, respectively). A median donor Breg p = 0.012). Our results revealed, for the first time, that high donor Breg content and their rapid recovery within 90 days after allo‐HSCT were associated with a decreased risk of aGVHD.


  • Open Access

    Correction: Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A: correlation with “Inhibitor” formation

    by Omid Reza Zekavat, Yasaman Movahednezhad, Amin Shahsavani, Sezaneh Haghpanah, Negin Shokrgozar, Hossein Golmoghaddam, Mehdi Kalani, Mohammad Reza Bordbar, Nargess Arandi

  • Open Access

    Abnormal frequency of the memory B cell subsets and plasmablasts in patients with congenital severe hemophilia A: correlation with “Inhibitor” formation

    by Omid Reza Zekavat, Yasaman Movahednezhad, Amin Shahsavani, Sezaneh Haghpanah, Negin Shokrgozar, Hossein Golmoghaddam, Mehdi Kalani, Mohammad Reza Bordbar, Nargess Arandi

    Background: Development of antibodies against infused Factor VIII (FVIII) or "inhibitors" represents a major challenge following FVIII replacement therapy in patients with hemophilia A (HA). Recent studies have shown that certain cellular compartments of the immune system contribute to the production of such antibodies. Herein, we determined the frequency of class-switched CD19+IgD−CD27+/non-class-switched CD19+IgD+CD27+ memory B cell subsets and CD19+CD27hiCD38hi plasmablasts in patients with severe HA and their association with the development of inhibitors in these patients. Methods: This cross-sectional case–control study enrolled 32 patients with severe HA, including 8 with and 24 without inhibitors, and 24 healthy individuals. The frequencies of the memory B cell subsets and plasmablasts were determined using flow cytometry. Results: The frequency of CD19+IgD+CD27+ non-class-switched memory B cells was significantly lower in patients with HA (including both patients with and without inhibitors) than in healthy controls. The percentages of both CD19+IgD−CD27+ class-switched and CD19+IgD+CD27+ non-class-switched memory B cells did not differ significantly between patients with and without inhibitors. HA patients with inhibitors had significantly higher proportions of CD19+CD27hiCD38hi plasmablasts than the control group as well as the inhibitor (-) ones. No significant correlation was observed between the inhibitor levels with the percentages of memory B cell subsets and plasmablasts. Conclusion: This study is the first to demonstrate a dysregulated proportion of CD19+IgD+CD27+ non-class-switched memory B cells and CD19+CD27hiCD38hi plasmablasts in patients with severe HA. Therefore, strategies targeting memory B-cell/plasmablast differentiation may have promising outcomes in the management of inhibitor formation in patients with severe HA.


  • Altered frequency of FOXP3+ regulatory T cells is associated with development of inhibitors in patients with severe hemophilia A

    by Nargess Arandi, Omid Reza Zekavat, Negin Shokrgozar, Amin Shahsavani, Hossein Golmoghaddam, Mehdi Kalani

    Introduction: The development of anti-factor VIII (FVIII) antibodies or "inhibitors" is a major complication following FVIII replacement therapy in patients with severe hemophilia A (HA), rendering the treatment inefficient. Data on the role of regulatory T cells (Tregs) in inhibitor formation in these patients are rare. Herein, we aimed to investigate whether a difference in the FOXP3+ Tregs is linked to the formation of the inhibitors in severe HA patients. Methods: In this cross-sectional study, 32 patients with severe HA (8 patients with inhibitors and 24 without inhibitors) and 24 healthy controls were enrolled. The frequency of FOXP3+ Tregs was determined using multicolor flow cytometry method. Results: Our results showed that the median level of CD4(+)CD25(+)FOXP3(+) Tregs did not significantly differ between HA patients and healthy controls and between HA patients with and without inhibitors (P > 0.05). However, patients with inhibitors had significantly lower amounts of CD4(+)CD25(similar to)FOXP3(+) Tregs compared to those without inhibitors as well as healthy controls (*P = 0.012 and *P = 0.004, respectively). The frequency of CD4(+)CD25(+) T cells was significantly higher in HA patients who developed inhibitors compared to the inhibitor-negative ones whereas they were lower in inhibitor-negative patients compared to the healthy controls (*P = 0.013 and *P = *0.029, respectively). The percentages of CD4+CD25+ T cells were positively correlated with the levels of inhibitors in HA patients (r = 0.45, *P = 0.021). Conclusion: Our data demonstrated for the first time that the CD4(+)CD25(similar to)FOXP3(+) Tregs might be implicated in the prevention of inhibitor formation in severe HA patients.


  • Selenium Supplementation Alter the Frequency of Th17 but not Th1/Th2 Lymphocytes in Diffuse Large B Cell Lymphoma Patients

    by Mehdi Dehghani, Mani Ramzi, Vida Moayed, Narges Rezaei, Mehdi Kalani, Hossein Golmoghaddam, Nargess Arandi

    Background: Selenium (Se) is a micronutrient, which has recently been proven to have a positive effect on the immune system of cancer patients, but the underlying mechanism is not clearly defined. In this randomized controlled trial, we evaluated the effect of three-month Se supplementation on the profile of CD4(+) T-helper subsets including IFN-gamma(+)/IL-4(-) Th1, IFN-gamma(-)/IL-4(+) Th2, and CD4(+)IL-17(+) Th17 cells in sixteen diffuse large B cell lymphoma (DLBCL) patients at stable remission phase who consumed Se (Se+) compared to the fourteen control patients who did not receive Se (Se-). Methods: The frequency of IFN-gamma(+)/IL-4(-) Th1, IFN-gamma(-)/IL-4(+) Th2, and CD4(+)IL-17(+) Th17 lymphocytes was determined using a four-color flow cytometry method. Results: The results revealed that three-month Se supplementation significantly decreased the proportion of CD4(+)IL-17(+) Th17 lymphocytes but not IFN-gamma(+)/IL-4(-) Th1 and IFN-gamma(-)/IL-4(+) Th2 subtypes in DLBCL patients at stable remission. Change in the percentage of IFN-gamma(+)/IL-4(-) Th1, IFN-gamma(-)/IL-4(+) Th2, and CD4(+)IL-17(+) Th17 cells did not significantly differ between Se+ and Se- groups. No positive correlation was observed between changes in different Th subpopulations in both Se+ and Se- groups. Conclusions: Taken together, three-month Se supplementation can reduce the proportion of CD4(+)IL-17(+) Th17 cells in DLBCL patients at stable remission phase. Larger population and longer follow-up of patients is necessary to specify the clinical significance of Se supplementation on the popularity of T-helper cells in DLBCL patients.


  • Open Access

    Study of the ratio of Treg/Th1 and Treg/Th2 lymphocytes in Hodgkin's lymphoma patients and its relationship with disease prognosis

    by Narges Arandi, Mehdi Dehghani, Mani Ramzi, Hossein Golmoghaddam, Narges Rezaei, Vida Moayed, Mehdi Kalani

    Background and purpose: CD4+CD25+FOXP3+ regulatory T cells (CD4+CD25+FOXP3+ Tregs) are a group of T lymphocytes that play an important role in regulating immune system responses by suppressing the activity of other T cells and establishing homeostasis in the immune system. Th1 and Th2 cells are other groups of CD4+ cells that play important functions ...

  • Open Access

    Atopy manifestations in pediatric patients with acute lymphoblastic leukemia: correlation assessment with interleukin-4 (IL-4) and IgE level

    by Omid Reza Zekavat, Elham Nikpendar, Sezaneh Haghpanah, Negin Shokrgozar, Seyed Javad Dehghani, Nargess Arandi

    Acute lymphoblastic leukemia (ALL) is the most common type of cancer in the age range of under 15 years old and accounts for 25–30% of all childhood cancers. Although conventional chemotherapy regimens are used to improve the overall survival rate, it has been associated with some complications, amongst which allergic manifestations with unknown mechanisms are more common. Our study compared serum IgE and IL-4 concentration, as a hallmark of allergic responses in pediatric ALL patients before and after 6 months of intensive (high-dose) chemotherapy, to show whether changes in the level of these markers may be associated with atopy. Serum level of IL-4 and IgE was measured using enzyme-linked immunosorbent assay (ELISA) method. The results showed that the level of IgE and IL-4 increased following chemotherapy in both ALL patients with and without atopy. In addition, post-chemotherapy treatment IgE and IL-4 levels were significantly elevated in patients with atopy compared to those without it. The difference between baseline and post-chemotherapy level of IgE and IL-4 was significantly higher in patients with atopy compared to those without it. To the best of our knowledge, this is the first study that showed a connection between post-chemotherapy allergic manifestations in pediatric ALL patients and IL-4 and IgE level. Flow cytometry analysis of the T-helper 2 (Th2) lymphocytes and other allergy-related T cell subsets like Tc2 and Th9 as well as the study of the genetic variations in atopy-related genes like IL-4/IL-4R, IL-5, IL-9, IL-13, and high affinity FcεRI IgE receptor and also HLA genes is necessary to clearly define the underlying mechanism responsible for post-chemotherapy hypersensitivity reaction in pediatric ALL patients.


  • The prognostic significance of immune checkpoint receptor expression in patients with lymphoma: Association with disease status and clinical outcomes

    by Negin Shokrgozar, Mehdi Dehghani, Hossein Golmoghaddam, Mohamad Moghadam, Narges Rezaei, Vida Moayed, Nargess Arandi

    Introduction: Little is known about the expression of immune checkpoint receptors in the peripheral blood of lymphoma patients. Herein, we assessed the expression of inhibitory checkpoint receptors, including CTLA‐4, PD‐1/PDL‐1, LAG‐3, and TIM‐3 in the peripheral blood of lymphoma patients and its correlation with the clinical outcomes of patients. Therefore, 47 classical Hodgkin lymphoma (cHL), 48 non‐Hodgkin lymphoma patients with diffuse large B‐cell lymphoma (DLBCL) subtype, and 30 healthy controls were recruited.Methods: The expression of inhibitory receptors was evaluated using SYBR Green real‐time PCR method.Results: CTLA‐4, LAG‐3, and TIM‐3 genes were significantly upregulated in both cHL and DLBCL patients compared to the healthy controls. In addition, the level of these molecules was differentially expressed in cHL and DLBCL patients at different disease phases compared to the healthy controls. The CTLA‐4 gene was highly expressed in newly diagnosed (ND) cHL patients compared to the relapsed ones. Relapsed DLBCL patients had significantly increased LAG‐3 expression compared to patients at remission, as well as ND patients. Regarding cHL patients, high CTLA‐4 expression was correlated with low lactate dehydrogenase level and better performance status, whereas the level of LAG‐3 was significantly elevated in patients with poor performance status. Lower initial PD‐1 expression was associated with improved disease‐free survival in cHL patients.Conclusions: Inhibitory immune checkpoint receptors are aberrantly expressed in the peripheral blood of cHL and DLBCL patients in which high LAG‐3 in DLBCL patients and PD‐1/LAG‐3 in cHL patients are associated with relapse occurrence and worse prognosis, respectively.